Erythropoietin Stimulating Agents Market Size & Share, by Agent (Epoetin Alpha, Epoetin Beta, Epoetin Omega, Epoetin Delta, Darbepoetin Alpha); Application (Cancer, Neural Disorders, Kidney Disorders, Anemia) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

Growth Drivers

• Growing Incidences of Chronic Kidney Disease and Cancer to Expand the Market: Chronic Kidney Disease is more common in older people aged 65 and above, with 38% prevalence, as compared with people aged 18-44 years (7%) and 45-64 years (13%) in the United States as per the CDC. The rising cases of this disorder along with other renal disorders that have a direct impact on the blood cells results in an increased demand for erythropoietin stimulating agents. Moreover, the growing incidences of various types of cancers, especially blood cancers, is another factor resulting in a high demand for blood cells in the body. These factors are anticipated to lead to the erythropoietin stimulating agents market growth over the forecast period. According to the statistics presented by the Leukemia & Lymphoma Society, it was suggested that a total of 176,200 people living in the United States were expected to be diagnosed with leukemia, lymphoma or myeloma in 2019. 
• Increase in Production of Biosimilar Drugs to Boost the Market Growth: Numerous pharmaceutical manufacturers are taking initiatives to develop and produce erythropoietin stimulating agents (ESAs) after the expiration of Amgen’s patent for Epogen. The growing commercialization of these drugs further results in reduction of their prices. This is anticipated to become another growth factor for the erythropoietin stimulating agents market in the upcoming years. 

Challenges

• Side Effects Associated with EPAs to Restrict the Market Growth: Erythropoietin stimulating agents have been known to exhibit certain side effects in patients taking them as drugs. These might include, fever, swelling, high blood pressure, nausea, dizziness and pain at the injection site. This is estimated to restrict the market growth during the forecast period.